Lbp Am Sa Takes $13.91 Million Position in Incyte Co. (NASDAQ:INCY)

Lbp Am Sa bought a new stake in shares of Incyte Co. (NASDAQ:INCY) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 201,311 shares of the biopharmaceutical company’s stock, valued at approximately $13,905,000. Lbp Am Sa owned 0.10% of Incyte as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of INCY. Venturi Wealth Management LLC acquired a new stake in shares of Incyte during the 3rd quarter valued at $65,000. GSA Capital Partners LLP boosted its stake in shares of Incyte by 26.5% during the 3rd quarter. GSA Capital Partners LLP now owns 6,453 shares of the biopharmaceutical company’s stock valued at $427,000 after buying an additional 1,351 shares during the period. Haverford Trust Co grew its position in Incyte by 1.8% in the third quarter. Haverford Trust Co now owns 7,796 shares of the biopharmaceutical company’s stock worth $515,000 after acquiring an additional 135 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. grew its position in Incyte by 21.8% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 6,406 shares of the biopharmaceutical company’s stock worth $423,000 after acquiring an additional 1,145 shares in the last quarter. Finally, CIBC Asset Management Inc grew its position in Incyte by 2.9% in the third quarter. CIBC Asset Management Inc now owns 25,303 shares of the biopharmaceutical company’s stock worth $1,673,000 after acquiring an additional 723 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Wall Street Analysts Forecast Growth

INCY has been the subject of several recent research reports. Cantor Fitzgerald reissued a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. William Blair reissued an “outperform” rating on shares of Incyte in a research report on Friday, December 13th. Wells Fargo & Company boosted their target price on shares of Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 19th. JMP Securities reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, February 11th. Finally, UBS Group began coverage on Incyte in a report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $75.25.

Incyte Stock Performance

Shares of NASDAQ INCY opened at $67.86 on Friday. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $71.75 and its two-hundred day moving average is $70.27. The company has a market cap of $13.13 billion, a P/E ratio of 251.34, a P/E/G ratio of 0.41 and a beta of 0.76. Incyte Co. has a 12 month low of $50.35 and a 12 month high of $83.95.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. On average, equities analysts expect that Incyte Co. will post 4.86 EPS for the current year.

Insider Buying and Selling at Incyte

In other Incyte news, insider Thomas Tray sold 650 shares of the firm’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $69.31, for a total transaction of $45,051.50. Following the completion of the transaction, the insider now owns 23,312 shares in the company, valued at $1,615,754.72. This trade represents a 2.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sheila A. Denton sold 599 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $69.99, for a total transaction of $41,924.01. Following the transaction, the executive vice president now owns 25,848 shares of the company’s stock, valued at approximately $1,809,101.52. This represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,670 shares of company stock valued at $2,026,933 in the last quarter. Corporate insiders own 17.60% of the company’s stock.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.